Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chasing green goals, corporations push car fleet managers toward EVs

Thu, 08th Sep 2022 13:58

MACCLESFIELD, England, Aug 12 (Reuters) - Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible.

In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid.

But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.

ALD will likely set a new goal that around 50% of its new vehicles will be either EVs or hybrid models by 2025 as corporations' hunger for zero-emission options to meet ESG targets keeps growing, Deputy Chief Executive Officer John Saffrett told Reuters.

Corporate clients are "all sitting there trying to figure out how they're going to meet their sustainability objectives," Saffrett said. "An obvious part of their footprint today that they're trying to address is their vehicle fleet."

Firms like ALD - which replaces its entire fleet every 42 months - play an important role in the auto industry, buying millions of vehicles globally that also help shape the future of the used car market when they come off lease.

ALD also leases cars to both firms and consumers on behalf of some major carmakers including Tesla Inc and Ford Motor Co.

According to industry data, leasing has grown as retail sales have fallen - the share of cars bought at retail in Europe fell to 45% in 2021 versus 55% in 2020.

BANISHING CARBON FROM SUPPLY CHAIN

France-based ALD is taking over Dutch rival LeasePlan, giving it a combined global fleet of around 3.5 million vehicles, as it focuses on scaling up its EV business.

Large ALD customers like AstraZeneca Plc have set electrification targets - the drugmaker wants its global fleet of 17,500 vehicles to be fully electric by 2025 - and are pushing carmakers to make those cars greener.

That intensifies the pressure on the auto industry to squeeze carbon and other harmful materials out of their supply chains.

But electrifying large fleets is easier said than done.

A lack of available public charging infrastructure means that for companies with sales representatives who drive long distances, only plug-in hybrids will work for now.

"The challenge you have with electrification as a corporate is you can't just switch drivers on day one," ALD's Saffrett said. "You'd love to, but it simply doesn't work."

In Africa, some parts of Asia and Europe, companies like AstraZeneca also face a lack of available EV or hybrid models.

In other areas, where a more rugged pickup truck is needed to reach the doctors served by such companies, suitable EVs are in short supply. AstraZeneca, for instance, has no choice but to buy fossil-fuel models in those regions, said Juliette White, the drugmaker's head of global sustainability.

Around 58% of AstraZeneca's global fleet are EVs, hybrids or plug-in hybrids.

"What we're absolutely clear about is if there is a plug-in hybrid or EV available, you're not getting a combustion engine model," White said at AstraZeneca's manufacturing site in Macclesfield in Northern England.

'LOW-HANGING FRUIT'

The rush to electrification is intensifying in Europe, where corporations face regulatory pressure to cut carbon footprints.

The most immediate focus is on so-called Scope 1 and Scope 2 emissions - those a company generates itself directly and indirectly. AstraZeneca's fleet, for instance, accounts for just under 17% of its emissions. At German agriculture and pharmaceuticals company Bayer, its fleet accounts for under 5% of emissions. Bayer is aiming for 30% of its global fleet of 26,000 light-duty trucks, SUVs and sedans to be electric within the next four years.

Going electric ticks both of those boxes.

"It's very low-hanging fruit and it's super easy to focus on your fleet," said Wolf-Dieter Hoppe, a Munich-based partner at consultancy Arthur D. Little.

Passenger cars and commercial vehicles are by far the largest asset class in Europe's leasing market. According to industry lobby group Leaseurope, in 2020 new vehicle leases totaled 244 billion euros ($249.5 billion), or 69% of all equipment leases.

AstraZeneca's White said large companies are also "pushing for greener and more sustainable EVs ... because otherwise what's the point?"

In Europe, EVs can also serve as a marketing tool for companies battling for qualified employees.

"Company cars can be a determining factor in the war for talent," said Piet Briers, Bayer's head of benefits. "As the availability of zero-emission car models as well as charging infrastructure continue to positively evolve, we see that employees are getting more engaged to opt for sustainable solutions."

But North America is catching up.

Again, though, the availability of suitable models and charging infrastructure will slow the adoption of EVs by corporate customers, he said.

"In 2019, I couldn't get anyone talking about this," Forbes said. "In 2022, all my clients want to talk about this evolution." ($1 = 0.9780 euro) (Reporting by Nick Carey in Macclesfield, England Editing by Matthew Lewis)

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.